Videos

Michael Abrams, MPH, PhD, senior health researcher at Public Citizen’s Health Research Group, discusses why classification of gabapentin as schedule V might be beneficial.

Jamie Wilkey, PharmD, founder of PGx Consulting Confidence Academy, discussed how pharmacists are utilizing pharmacogenomics for their patients.

Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses how the beliefs and perceptions of cancer among adults living in rural areas compared to those of adults living in urban areas.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses how dosing for rucaparib treatment is assessed to treat patients with ovarian cancer.

Lakyn Husinka, PharmD, discussed new treatment options and pharmacists' role in treating patients with breast cancer.

Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses rural residents’ beliefs and perceptions of cancer-related information in comparison with those of urban residents.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the efficacy of rucaparib for approved indications based on clinical trial results.

Zachary Nelson, PharmD, BCIDP, BCPS, discussed the past 2 influenza seasons and how they could help predict vaccination and illness rates.

David Zgarrick, PhD, FAPhA, professor in the department of pharmacy and health systems sciences at Northeastern University, also addresses what the future of the pharmacy profession could look like.

Drs Anthony Perissinotti and Kirollos Hanna provide some important considerations for pharmacists in treating chronic lymphocytic leukemia.

Experts discuss the potential future use of CAR T-cell therapy and bispecific therapeutics for chronic lymphocytic leukemia based on data presented at ASH 2021.

Dr Anthony Perissinotti details an effective new therapy on the horizon in chronic lymphocytic leukemia.

Katie Tobon, PharmD, BCOP, and Javier Pinilla-Ibarz, MD, PhD, discuss factors to consider when selecting a BTK inhibitor for CLL therapy, including cytogenetic abnormalities as well as patient- and treatment-related factors.

Bill Ladwig, senior vice president of professional services at Lewis Drug, discussed the pharmacy's 80-year history.

Whitney Hummel, AAS, CPhT-Adv, CSPT, RYT, pharmacy operations coordinator at the Florida Cancer Specialists & Research Institute, discusses burnout for pharmacy technicians.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses the origin of the historical idea that sexual dysfunction in women is primarily based in emotional and/or psychological conditions.

Peter Pitts, a former FDA associate commissioner and president of the Center for Medicine in the Public Interest, discusses the implications of Robert Califf’s appointment to lead the FDA on the future of the agency’s review system.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses how rucaparib is currently used when treating patients with ovarian cancer.

Diane McCarthy, director of biologics pipeline development at US Pharmacopeia (USP), discusses USP’s development of mRNA quality guidelines to help companies and regulators bring innovative medicines to market faster.

In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the mechanism of action of rucaparib in recurrent and second line ovarian cancer, fallopian tube cancer, and peritoneal cancer.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses how hypoactive sexual desire disorder in women was defined and treated historically.

Dr Ryan Jacobs evaluates the use of chemotherapy options for first-line treatment of CLL.

Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, share considerations for approaching an individualized treatment regimen for patients with CLL.

Glecaprevir and pibrentasvir (Mavyret) is indicated for the treatment of chronic hepatitis C virus genotype 1-6 infections without cirrhosis or with compensated cirrhosis.

Steven Sims, MD, discussed his upcoming research into how transnasal esophagoscopy could help address disparities in esophageal cancer diagnoses.

Troy Trygstad, PharmD, PhD, MBA, executive director of CPESN USA, discussed how consumers' expectations are changing the future of pharmacy.

Anthony Perissinotti and Kirollos Hanna discuss considerations for selecting treatment regimens in chronic lymphocytic leukemia.

Chronic lymphocytic leukemia experts debate how to prevent or reduce the risk of tumor lysis in patients.